Proteomic analysis of glioblastomas: what is the best brain control sample?
暂无分享,去创建一个
Jean-Michel Lemée | Philippe Menei | Charles Pineau | Anne Clavreul | Marie de Tayrac | C. Pineau | J. Lemée | V. Quillien | A. Clavreul | P. Menei | E. Com | Emmanuelle Com | Tony Avril | Véronique Quillien | M. de Tayrac | T. Avril
[1] D. Hayes,et al. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy , 2010, British Journal of Cancer.
[2] C. Brennan,et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.
[3] D. Hafler,et al. Protective and therapeutic role for αB-crystallin in autoimmune demyelination , 2007, Nature.
[4] S. Atlas,et al. Magnetic resonance image–guided proteomics of human glioblastoma multiforme , 2003, Journal of magnetic resonance imaging : JMRI.
[5] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[6] Mahlon D. Johnson,et al. Protein Profiling in Brain Tumors Using Mass Spectrometry , 2004, Clinical Cancer Research.
[7] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] Jean Mosser,et al. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach , 2011, Proteome Science.
[9] Ashraf A Khalil,et al. Biomarker discovery: A proteomic approach for brain cancer profiling , 2007, Cancer science.
[10] Oscar Persson,et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients , 2010, Proteomics. Clinical applications.
[11] L. Claesson‐Welsh,et al. alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. , 2008, Blood.
[12] P. Parsons,et al. Alpha B‐Crystallin, a New Independent Marker for Poor Prognosis in Head and Neck Cancer , 2005, The Laryngoscope.
[13] D. Hafler,et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. , 2007, Nature.
[14] R. Kiss,et al. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Vani Santosh,et al. Differential protein expression in human gliomas and molecular insights , 2005, Proteomics.
[16] J. David,et al. Effects of hypoxia on stress proteins in the piglet heart at birth , 2005, Cell stress & chaperones.
[17] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[18] C. Houser,et al. Neuroanatomical clues to altered neuronal activity in epilepsy: From ultrastructure to signaling pathways of dentate granule cells , 2012, Epilepsia.
[19] C. Shin,et al. Differential Expression of Activating Transcription Factor-2 and c-Jun in the Immature and Adult Rat Hippocampus Following Lithium-Pilocarpine Induced Status Epilepticus , 2009, Yonsei medical journal.
[20] Bruno Zanotti,et al. Proteomic studies on low- and high-grade human brain astrocytomas. , 2005, Journal of proteome research.
[21] P. Black,et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] W. Hamel,et al. Pattern of Recurrence following Local Chemotherapy with Biodegradable Carmustine (BCNU) Implants in Patients with Glioblastoma , 2004, Journal of Neuro-Oncology.
[23] S. Niclou,et al. Glioma proteomics: status and perspectives. , 2010, Journal of proteomics.
[24] M. Oshimura,et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. , 2003, Biochemical and biophysical research communications.
[25] Friedrich Lottspeich,et al. ICPL labeling strategies for proteome research. , 2011, Methods in molecular biology.
[26] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[27] Chae-Yong Kim,et al. Tissue Expression of Manganese Superoxide Dismutase Is a Candidate Prognostic Marker for Glioblastoma , 2009, Oncology.
[28] J. Mosser,et al. Isolation of a new cell population in the glioblastoma microenvironment , 2012, Journal of Neuro-Oncology.
[29] Identification of Glioma Neovascularization-related Proteins by Using MALDI-FTMS and Nano-LC Fractionation to Microdissected Tumor Vessels* , 2007, Molecular & Cellular Proteomics.
[30] H. Sandler,et al. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. , 1991, Journal of neurosurgery.
[31] Hans-Peter Lenhof,et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. , 2009, Journal of proteome research.
[32] J. Kellermann. ICPL--isotope-coded protein label. , 2008, Methods in molecular biology.
[33] G. Iacob,et al. Current data and strategy in glioblastoma multiforme , 2009, Journal of medicine and life.
[34] Yu Shyr,et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.
[35] A. Schmidt,et al. A novel strategy for quantitative proteomics using isotope‐coded protein labels , 2005, Proteomics.
[36] Akira Yamaura,et al. Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis , 2004, Cancer Research.
[37] A. Vortmeyer,et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme , 2004, Oncogene.
[38] E. Wawrousek,et al. Exacerbation of retinal degeneration in the absence of alpha crystallins in an in vivo model of chemically induced hypoxia. , 2008, Experimental eye research.
[39] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[40] P. Svenningsson,et al. The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2‐20 and peptides as sample quality indicators , 2007, Proteomics.
[41] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[42] Philippe Menei,et al. Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. , 2012, Journal of proteomics.